Cartesian Therapeutics (RNAC) Goodwill (2023 - 2026)

Cartesian Therapeutics (RNAC) has 4 years of Goodwill data on file, last reported at $48.2 million in Q1 2026.

• Goodwill for Q1 2026 came in at $48.2 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.2 million (changed 0.0% YoY), and the FY2025 annual result was $48.2 million, changed 0.0% from the prior year.
• Goodwill steadied at $48.2 million in Q1 2026 per RNAC's latest filing, from $48.2 million in the prior quarter.
• Over five years, Goodwill peaked at $48.2 million in Q4 2023 and troughed at $48.2 million in Q4 2023.
• A 4-year average of $48.2 million and a median of $48.2 million in 2023 frame the typical range for Goodwill.
• On a YoY basis, Goodwill climbed as much as 0.0% in 2024 and fell as far as 0.0% in 2024.
• A 4-year view of Goodwill shows it stood at $48.2 million in 2023, then changed by 0.0% to $48.2 million in 2024, then changed by 0.0% to $48.2 million in 2025, then changed by 0.0% to $48.2 million in 2026.
• Business Quant data shows RNAC's Goodwill at $48.2 million in Q1 2026, $48.2 million in Q4 2025, and $48.2 million in Q3 2025.